Annual Accounts Payable
$1.69 M
-$237.00 K-12.31%
31 December 2023
Summary:
ReShape Lifesciences annual accounts payable is currently $1.69 million, with the most recent change of -$237.00 thousand (-12.31%) on 31 December 2023. During the last 3 years, it has fallen by -$1.97 million (-53.79%). RSLS annual accounts payable is now -60.38% below its all-time high of $4.26 million, reached on 31 December 2019.RSLS Accounts Payable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Accounts Payable
$2.10 M
+$1.07 M+104.37%
30 September 2024
Summary:
ReShape Lifesciences quarterly accounts payable is currently $2.10 million, with the most recent change of +$1.07 million (+104.37%) on 30 September 2024. Over the past year, it has increased by +$643.00 thousand (+43.98%). RSLS quarterly accounts payable is now -52.46% below its all-time high of $4.43 million, reached on 30 September 2018.RSLS Quarterly Accounts Payable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
RSLS Accounts Payable Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -12.3% | +44.0% |
| 3 y3 years | -53.8% | -32.4% |
| 5 y5 years | +3.8% | -45.3% |
RSLS Accounts Payable High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3 years | -53.8% | at low | -41.5% | +104.4% |
| 5 y | 5 years | -60.4% | +3.8% | -50.6% | +104.4% |
| alltime | all time | -60.4% | +4926.8% | -52.5% | +6164.9% |
ReShape Lifesciences Accounts Payable History
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2024 | - | $2.10 M(+104.4%) |
| June 2024 | - | $1.03 M(-21.6%) |
| Mar 2024 | - | $1.31 M(-22.2%) |
| Dec 2023 | $1.69 M(-12.3%) | $1.69 M(+15.5%) |
| Sept 2023 | - | $1.46 M(-8.7%) |
| June 2023 | - | $1.60 M(-19.8%) |
| Mar 2023 | - | $2.00 M(+3.7%) |
| Dec 2022 | $1.93 M(-44.5%) | $1.93 M(-3.3%) |
| Sept 2022 | - | $1.99 M(-20.7%) |
| June 2022 | - | $2.51 M(-30.2%) |
| Mar 2022 | - | $3.60 M(+3.7%) |
| Dec 2021 | $3.47 M(-5.1%) | $3.47 M(+11.4%) |
| Sept 2021 | - | $3.11 M(+0.5%) |
| June 2021 | - | $3.10 M(-14.9%) |
| Mar 2021 | - | $3.64 M(-0.5%) |
| Dec 2020 | $3.65 M(-14.3%) | $3.65 M(-2.8%) |
| Sept 2020 | - | $3.76 M(-8.8%) |
| June 2020 | - | $4.12 M(+9.9%) |
| Mar 2020 | - | $3.75 M(-12.0%) |
| Dec 2019 | $4.26 M(+162.0%) | $4.26 M(+10.7%) |
| Sept 2019 | - | $3.85 M(+16.4%) |
| June 2019 | - | $3.31 M(+26.2%) |
| Mar 2019 | - | $2.62 M(+61.2%) |
| Dec 2018 | $1.63 M(+49.5%) | $1.63 M(-63.3%) |
| Sept 2018 | - | $4.43 M(+5.4%) |
| June 2018 | - | $4.20 M(+44.0%) |
| Mar 2018 | - | $2.92 M(+168.1%) |
| Dec 2017 | $1.09 M(-17.0%) | $1.09 M(+54.0%) |
| Sept 2017 | - | $706.50 K(-36.3%) |
| June 2017 | - | $1.11 M(+107.9%) |
| Mar 2017 | - | $533.60 K(-59.3%) |
| Dec 2016 | $1.31 M(+662.2%) | $1.31 M(+92.7%) |
| Sept 2016 | - | $680.80 K(+90.7%) |
| June 2016 | - | $357.00 K(+36.6%) |
| Mar 2016 | - | $261.40 K(+51.9%) |
| Date | Annual | Quarterly |
|---|---|---|
| Dec 2015 | $172.10 K(-56.9%) | $172.10 K(-12.1%) |
| Sept 2015 | - | $195.80 K(-56.2%) |
| June 2015 | - | $447.20 K(+841.5%) |
| Mar 2015 | - | $47.50 K(-88.1%) |
| Dec 2014 | $399.30 K(+213.7%) | $399.30 K(+673.8%) |
| Sept 2014 | - | $51.60 K(-72.5%) |
| June 2014 | - | $187.40 K(-31.6%) |
| Mar 2014 | - | $274.00 K(+115.2%) |
| Dec 2013 | $127.30 K(-62.6%) | $127.30 K(-29.4%) |
| Sept 2013 | - | $180.20 K(-20.8%) |
| June 2013 | - | $227.40 K(-49.4%) |
| Mar 2013 | - | $449.20 K(+31.9%) |
| Dec 2012 | $340.60 K(-21.6%) | $340.60 K(+16.4%) |
| Sept 2012 | - | $292.70 K(+196.3%) |
| June 2012 | - | $98.80 K(-62.4%) |
| Mar 2012 | - | $262.60 K(-39.5%) |
| Dec 2011 | $434.40 K(+247.0%) | $434.40 K(+66.2%) |
| Sept 2011 | - | $261.30 K(+113.5%) |
| June 2011 | - | $122.40 K(-76.1%) |
| Mar 2011 | - | $512.80 K(+309.6%) |
| Dec 2010 | $125.20 K(+272.6%) | $125.20 K(-63.5%) |
| Sept 2010 | - | $343.20 K(+80.9%) |
| June 2010 | - | $189.70 K(+154.3%) |
| Mar 2010 | - | $74.60 K(+122.0%) |
| Dec 2009 | $33.60 K(-79.4%) | $33.60 K(-84.0%) |
| Sept 2009 | - | $210.30 K(+52.4%) |
| June 2009 | - | $138.00 K(+5.4%) |
| Mar 2009 | - | $130.90 K(-19.9%) |
| Dec 2008 | $163.40 K(-45.6%) | $163.40 K(-65.9%) |
| Sept 2008 | - | $479.30 K(-12.9%) |
| June 2008 | - | $550.20 K(+10.2%) |
| Mar 2008 | - | $499.10 K(+66.2%) |
| Dec 2007 | $300.30 K(-55.8%) | $300.30 K(+26.0%) |
| Sept 2007 | - | $238.40 K(-64.9%) |
| Dec 2006 | $678.80 K(+114.2%) | $678.80 K(+114.2%) |
| Dec 2005 | $316.90 K | $316.90 K |
FAQ
- What is ReShape Lifesciences annual accounts payable?
- What is the all time high annual accounts payable for ReShape Lifesciences?
- What is ReShape Lifesciences annual accounts payable year-on-year change?
- What is ReShape Lifesciences quarterly accounts payable?
- What is the all time high quarterly accounts payable for ReShape Lifesciences?
- What is ReShape Lifesciences quarterly accounts payable year-on-year change?
What is ReShape Lifesciences annual accounts payable?
The current annual accounts payable of RSLS is $1.69 M
What is the all time high annual accounts payable for ReShape Lifesciences?
ReShape Lifesciences all-time high annual accounts payable is $4.26 M
What is ReShape Lifesciences annual accounts payable year-on-year change?
Over the past year, RSLS annual accounts payable has changed by -$237.00 K (-12.31%)
What is ReShape Lifesciences quarterly accounts payable?
The current quarterly accounts payable of RSLS is $2.10 M
What is the all time high quarterly accounts payable for ReShape Lifesciences?
ReShape Lifesciences all-time high quarterly accounts payable is $4.43 M
What is ReShape Lifesciences quarterly accounts payable year-on-year change?
Over the past year, RSLS quarterly accounts payable has changed by +$643.00 K (+43.98%)